Nagi B Kumar1, Gwendolyn P Quinn2, Mark G Alexandrow3, Jhanelle Gray4, Michael Schell5, Steve Sutton5, Eric B Haura4. 1. Departments of Epidemiology, University of South Florida College of Medicine, Tampa, Florida, USA. 2. Health Outcomes and Behavior, University of South Florida College of Medicine, Tampa, Florida, USA. 3. Molecular Oncology Thoracic Oncology, University of South Florida College of Medicine, Tampa, Florida, USA. 4. Biostatistics, University of South Florida College of Medicine, Tampa, Florida, USA. 5. H Lee Moffitt Cancer Center & Research Institute, the University of South Florida College of Medicine, Tampa, Florida, USA.
Abstract
While chemoprevention with botanicals shows promise in reducing cancer risk, recruitment and retention of participants for trials continues to be costly and presents unique challenges. Knowledge of interest, willingness of target populations and evaluation of design challenges are critical to improve accrual in these chemoprevention trials. OBJECTIVE: The study assessed interest and willingness of former smokers to participate in a chemoprevention trial using a botanical agent. METHODS: An introductory letter and survey instrument were mailed to 609 consecutive, former heavy smokers, with no cancer, from a database of 826 subjects at the Moffitt Cancer Center. RESULTS: 202 (40.4%) subjects returned completed surveys. 92-96% reported interest in receiving free lung exams and knowing their lung cancer risk. 88% were interested in participating in a trial evaluating a botanical agent for lung cancer prevention. Over 92% of subjects reported willingness to comply with study requirements; multiple blood draws and trips to the Center, spiral CTs and chest x-rays. Subjects were relatively less enthusiastic (73-79%) about bronchoscopy, taking multiple study agents and assignment to placebo arm. CONCLUSIONS: Our study strongly suggests feasibility, highlights potential challenges and the significant interest and willingness of this exceptionally high risk population to participate in chemoprevention trials.
While chemoprevention with botanicals shows promise in reducing cancer risk, recruitment and retention of participants for trials continues to be costly and presents unique challenges. Knowledge of interest, willingness of target populations and evaluation of design challenges are critical to improve accrual in these chemoprevention trials. OBJECTIVE: The study assessed interest and willingness of former smokers to participate in a chemoprevention trial using a botanical agent. METHODS: An introductory letter and survey instrument were mailed to 609 consecutive, former heavy smokers, with no cancer, from a database of 826 subjects at the Moffitt Cancer Center. RESULTS: 202 (40.4%) subjects returned completed surveys. 92-96% reported interest in receiving free lung exams and knowing their lung cancer risk. 88% were interested in participating in a trial evaluating a botanical agent for lung cancer prevention. Over 92% of subjects reported willingness to comply with study requirements; multiple blood draws and trips to the Center, spiral CTs and chest x-rays. Subjects were relatively less enthusiastic (73-79%) about bronchoscopy, taking multiple study agents and assignment to placebo arm. CONCLUSIONS: Our study strongly suggests feasibility, highlights potential challenges and the significant interest and willingness of this exceptionally high risk population to participate in chemoprevention trials.
Entities:
Keywords:
Chemoprevention; Former smokers; Lung Cancer
Authors: Joyce A O'Shaughnessy; Gary J Kelloff; Gary B Gordon; Andrew J Dannenberg; Waun Ki Hong; Carol J Fabian; Caroline C Sigman; Monica M Bertagnolli; Steven P Stratton; Stephen Lam; William G Nelson; Frank L Meyskens; David S Alberts; Michele Follen; Anil K Rustgi; Vali Papadimitrakopoulou; Peter T Scardino; Adi F Gazdar; Lee W Wattenberg; Michael B Sporn; Wael A Sakr; Scott M Lippman; Daniel D Von Hoff Journal: Clin Cancer Res Date: 2002-02 Impact factor: 12.531
Authors: Jenny T Mao; Michael D Roth; Michael C Fishbein; Denise R Aberle; Zuo-Feng Zhang; Jian Yu Rao; Donald P Tashkin; Lee Goodglick; E Carmack Holmes; Robert B Cameron; Steven M Dubinett; Robert Elashoff; Eva Szabo; David Elashoff Journal: Cancer Prev Res (Phila) Date: 2011-07
Authors: Naveena B Janakiram; Altaf Mohammed; Yuting Zhang; Chang-In Choi; Carl Woodward; Peter Collin; Vernon E Steele; Chinthalapally V Rao Journal: Cancer Prev Res (Phila) Date: 2010-01
Authors: Jhanelle E Gray; Soner Altiok; Mark G Alexandrow; Frank W Walsh; Jian Chen; Michael J Schell; Datchen Fritz Tai; Gerold Bepler Journal: Cancer Date: 2012-10-12 Impact factor: 6.860